Positives

• In a Russian clinical series of 44 patients with post-stroke and post-head-injury cognitive sequelae, Pinealon roughly doubled the response rate over controls and cut headache, sleep, and fatigue scores by 50 to 75 percent PMC.
  
  
• Mouse Alzheimer's models showed the EDR tripeptide upregulated BDNF, NGF, and antioxidant enzymes, mechanisms a long COVID patient with neuroinflammation may want to engage MDPI.
  
  

Negatives

• A patient evaluating quality of evidence will find that every Pinealon study traces back to Khavinson's institute, with no independent replication and roughly half the publications in Russian only PMC.
  
  
• A patient should note there are no randomized controlled trials in long COVID specifically, only adjacent neurodegeneration data MDPI.
  
  

Hurdles & Side Effects

• A US patient cannot get Pinealon as an approved drug and must purchase from research-chemical or overseas vendors with no purity assurance PMC.
  
  
• A patient self-administering must reconstitute lyophilized peptide, refrigerate carefully, and dose by injection or nasal atomization without clinician oversight MDPI.